Summary of the results of imatinib mesylate therapy in CML after postallogeneic stem cell transplantation
| Study . | No. treated . | CML phase . | Prior IFN-α/DLI . | Median time from SCT to therapy, mo (range) . | % response CHR/major CG response . | Side effects, comments . |
|---|---|---|---|---|---|---|
| Chambon-Pautas et al25 | 15 | CP-12; > CP-3 | 12/9 | (9-132) | 80/80 | Granulocytopenia 4 (27%), thrombocytopenia 1 (7%) |
| Wassmann et al26 | 13 | CP-1; > CP-12 | NS | 6.5 (2-50) | 54/46 | Gastrointestinal |
| Soiffer et al27 | 16 | > CP-12; Ph+ALL-4 | NS/5 | 12 (2-24) | 50/37 | Liver dysfunction possibly from GVHD-3 |
| Ullmann et al28 | 17 | CP-10; > CP-7 | NS | 17 (2-234) | 76/71 | Gastrointestinal, myelosuppression 6 of 15 (40%) |
| Moreira et al29 | 13 | CP-5; > CP-8 | NS/5 | 15 (5-68) | 100/23 | Severe toxicities 5 of 13 (38%), myelosuppression 7 of 13 (53%) |
| Present study | 28 | CP-5; > CP-23 | 9/13 | 9 (1-137) | 75/52 | Severe GVHD 3 of 28 (11%), granulocytopenia 43%, thrombocytopenia 27% |
| Study . | No. treated . | CML phase . | Prior IFN-α/DLI . | Median time from SCT to therapy, mo (range) . | % response CHR/major CG response . | Side effects, comments . |
|---|---|---|---|---|---|---|
| Chambon-Pautas et al25 | 15 | CP-12; > CP-3 | 12/9 | (9-132) | 80/80 | Granulocytopenia 4 (27%), thrombocytopenia 1 (7%) |
| Wassmann et al26 | 13 | CP-1; > CP-12 | NS | 6.5 (2-50) | 54/46 | Gastrointestinal |
| Soiffer et al27 | 16 | > CP-12; Ph+ALL-4 | NS/5 | 12 (2-24) | 50/37 | Liver dysfunction possibly from GVHD-3 |
| Ullmann et al28 | 17 | CP-10; > CP-7 | NS | 17 (2-234) | 76/71 | Gastrointestinal, myelosuppression 6 of 15 (40%) |
| Moreira et al29 | 13 | CP-5; > CP-8 | NS/5 | 15 (5-68) | 100/23 | Severe toxicities 5 of 13 (38%), myelosuppression 7 of 13 (53%) |
| Present study | 28 | CP-5; > CP-23 | 9/13 | 9 (1-137) | 75/52 | Severe GVHD 3 of 28 (11%), granulocytopenia 43%, thrombocytopenia 27% |
> CP indicates beyond chronic phase; NS, not specified.